GlassScriptPhysician profile
Virginia A Campbell
NPI 1255398152
$5,834.61
in general payments reported to CMS, 2019-2025
43 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $758 · 2021: $765 · 2022: $536 · 2023: $792 · 2024: $1,101 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $644.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $625.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $608.92 | 2021-2025 | Ubrelvy, Qulipta, Synthroid |
| Glaxosmithkline, LLC. | $482.54 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $401.45 | 2019-2021 | |
| Amgen INC. | $398.76 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $253.67 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Janssen Pharmaceuticals, INC | $226.53 | 2020-2022 | |
| Pfizer INC. | $218.08 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.06 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $180.15 | 2019-2025 | |
| Corium, LLC | $166.97 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $155.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $154.77 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $135.47 | 2020-2024 | Livalo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.